- Home
- CHEK vs VIVS Comparison
CHEK vs VIVS Comparison
Compare CHEK & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- VIVS
- Stock Information
- Founded
- CHEK 2004
- VIVS 2007
- Country
- CHEK Israel
- VIVS United States
- Employees
- CHEK N/A
- VIVS N/A
- Industry
- CHEK Medical Electronics
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHEK Health Care
- VIVS Health Care
- Exchange
- CHEK Nasdaq
- VIVS Nasdaq
- Market Cap
- CHEK 4.4M
- VIVS 4.2M
- IPO Year
- CHEK 2015
- VIVS N/A
- Fundamental
- Price
- CHEK N/A
- VIVS $1.60
- Analyst Decision
- CHEK
- VIVS
- Analyst Count
- CHEK 0
- VIVS 0
- Target Price
- CHEK N/A
- VIVS N/A
- AVG Volume (30 Days)
- CHEK 28.3K
- VIVS 42.9K
- Earning Date
- CHEK 08-14-2025
- VIVS 07-11-2025
- Dividend Yield
- CHEK N/A
- VIVS N/A
- EPS Growth
- CHEK N/A
- VIVS N/A
- EPS
- CHEK N/A
- VIVS N/A
- Revenue
- CHEK N/A
- VIVS $144,000.00
- Revenue This Year
- CHEK N/A
- VIVS $42.38
- Revenue Next Year
- CHEK N/A
- VIVS $15.42
- P/E Ratio
- CHEK N/A
- VIVS N/A
- Revenue Growth
- CHEK N/A
- VIVS 32.11
- 52 Week Low
- CHEK $0.56
- VIVS $1.41
- 52 Week High
- CHEK $3.04
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- CHEK 41.81
- VIVS N/A
- Support Level
- CHEK $0.75
- VIVS N/A
- Resistance Level
- CHEK $0.86
- VIVS N/A
- Average True Range (ATR)
- CHEK 0.03
- VIVS 0.00
- MACD
- CHEK 0.00
- VIVS 0.00
- Stochastic Oscillator
- CHEK 19.59
- VIVS 0.00
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.